pentylenetetrazole has been researched along with Down Syndrome in 10 studies
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.
pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trisomy 21 was first described as a syndrome in the middle of the nineteenth century and associated to a chromosomic anomaly one hundred years later: the most salient feature of this syndrome is a mental retardation of variable intensity." | 2.46 | [New perspectives on molecular and genic therapies in Down syndrome]. ( Delabar, JM, 2010) |
| "Pentylenetetrazole effectiveness was dependent on the time of treatment; cognitive performance improved after treatment during the light (inactive) phase, but not during the dark (active) phase." | 1.39 | Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. ( Blank, M; Buckmaster, P; Chuluun, B; Colas, D; Garner, CC; Heller, HC; Warrier, D; Wetmore, DZ, 2013) |
| " Thus we aim to evaluate the effect of an increase in Cstb gene dosage on spontaneous epileptic activity and susceptibility to PTZ-induced seizure." | 1.37 | Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB. ( Bizot, JC; Brault, V; Costet, N; Hérault, Y; Martin, B, 2011) |
| "Seizures are a common phenotype in all of these neurological disorders, yet the underlying molecular mechanism(s) of seizure induction and propagation remain largely unknown." | 1.36 | Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures. ( Malter, JS; Westmark, CJ; Westmark, PR, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colas, D | 1 |
| Chuluun, B | 1 |
| Warrier, D | 1 |
| Blank, M | 2 |
| Wetmore, DZ | 1 |
| Buckmaster, P | 1 |
| Garner, CC | 3 |
| Heller, HC | 2 |
| Martínez-Cué, C | 2 |
| Delatour, B | 1 |
| Potier, MC | 1 |
| Ruby, NF | 1 |
| Fernandez, F | 2 |
| Zhang, P | 1 |
| Klima, J | 1 |
| Delabar, JM | 1 |
| Westmark, CJ | 1 |
| Westmark, PR | 1 |
| Malter, JS | 1 |
| Brault, V | 1 |
| Martin, B | 1 |
| Costet, N | 1 |
| Bizot, JC | 1 |
| Hérault, Y | 1 |
| Morishita, W | 1 |
| Zuniga, E | 1 |
| Nguyen, J | 1 |
| Malenka, RC | 1 |
| Buckley, F | 1 |
| Sacks, B | 1 |
| Rueda, N | 1 |
| Flórez, J | 1 |
| Arshavskiĭ, VV | 1 |
| Vaĭndrukh, FA | 1 |
2 reviews available for pentylenetetrazole and Down Syndrome
| Article | Year |
|---|---|
Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists.
Topics: Animals; Benzodiazepines; Down Syndrome; Drug Inverse Agonism; GABA-A Receptor Antagonists; Humans; | 2014 |
[New perspectives on molecular and genic therapies in Down syndrome].
Topics: Animals; Catechin; Chromosomes, Human, Pair 21; Disease Models, Animal; Down Syndrome; Droxidopa; Dr | 2010 |
8 other studies available for pentylenetetrazole and Down Syndrome
| Article | Year |
|---|---|
Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome.
Topics: Animals; Behavior, Animal; Circadian Rhythm; Cognition; Disease Models, Animal; Down Syndrome; Elect | 2013 |
Circadian locomotor rhythms are normal in Ts65Dn "Down syndrome" mice and unaffected by pentylenetetrazole.
Topics: Animals; Circadian Rhythm; Darkness; Disease Models, Animal; Down Syndrome; Mice; Motor Activity; Pe | 2010 |
Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures.
Topics: Acoustic Stimulation; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Convulsants; Down | 2010 |
Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB.
Topics: Animals; Atrophy; Brain; Cystatin B; Disease Models, Animal; Disease Susceptibility; Down Syndrome; | 2011 |
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.
Topics: Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Down Syndrome; Electric Stim | 2007 |
Drug treatment improves memory in mice.
Topics: Animals; Central Nervous System Stimulants; Chromosomes, Human, Pair 21; Cyclopentanes; Disease Mode | 2007 |
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.
Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Disease Mod | 2008 |
[Electroencephalographic characteristics of Down's syndrome. A comparative study of patients with and without paroxysmal epileptiform manifestations].
Topics: Adolescent; Adult; Age Factors; Child; Down Syndrome; Electroencephalography; Female; Humans; Light; | 1969 |